Abstract:Twice-daily combination therapy of inhaled corticosteroids and long-acting beta2-adrenoceptor agonists (LABA) is now established as a most effective treatment for moderate to severe asthma and is available in a combined single inhaler. The benefits of combination therapy include better day-to-day control and a reduction in exacerbations compared with monotherapy with inhaled corticosteroids at a lower dose. Total control of asthma, defined as no daytime or night-time symptoms, no use of rescue beta2-adrenoceptor agonists (beta2-agonists), no exacerbations and a peak flow rate of >80% predicted, may be achieved with the use of combined salmeterol/fluticasone in up to 41% of patients with moderate to severe asthma, compared with only 28% of patients treated with fluticasone alone. Adjustable maintenance dosing with budesonide/formoterol may provide better control when compared with fixed-dosing combination regimens. Other therapies combining effectively with inhaled corticosteroids include slow-release theophylline and leukotriene inhibitors, montelukast and zafirlukast, but LABA are the most efficacious. Molecular interactions between corticosteroids and beta2-adrenoceptors may underlie the clinical added benefits of combination therapy. Corticosteroids may increase the number of beta2-adrenoceptors and their coupling with Gs proteins, while beta2-agonists may induce glucocorticoid receptor nuclear translocation, activate transcription factor/enhancer binding protein C/EBPalpha together with corticosteroids, or phosphorylate corticosteroid receptors. The combination of corticosteroids and LABA potentiates inhibition of interleukin-8 and eotaxin release from human airway smooth muscle cells and granulocyte-macrophage colony-stimulating factor release from epithelial cells, and also the inhibition of airway smooth muscle cell proliferation. It is important to determine whether there is a potentiating effect of combination therapy compared with corticosteroid treatment alone on airway inflammation and airway wall remodelling. Improvements in combination therapy include a once-daily preparation and possible combination of inhaled corticosteroids with newer drugs such as phosphodiesterase IV inhibitors.

Treatment of chronic moderate asthma by corticosteroid inhalation with controlled released theophylline or beta2-agonist

Effects of inhalation therapy in the management of moderate to severe acute asthma exacerbations

Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma

Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group

Effect and its clinical significance of different dose of glucocorticoids on inflammation mediators in patients with acute exacerbation of chronic obstructive pulmonary diseases

The effect of inhaled glucocorticoid aerosol in pulmonary function and serum cortisol for patients with asthma

Treatment efficacy evaluation of standardized management for children with asthma

Comparison of Leukotriene Receptor Antagonist and Theophylline in Addition to Inhaled Corticosteroid in Adult Asthma: A Meta-Analysis

Treatment of Inhaled Corticosteroids Combined with Theophylline in COPD Based on Effective Phenotypes

A Three-Month Non-Interventional Study of Asthma Treatment with Budesonide/Formoterol

Clinical Efficacy of Budesonide and Formoterol Fumarate Powder in the Treatment of Patients with Bronchial Asthma and Its Effect on the Serum Levels of Inflammatory Factors

Observation on the clinical efficacy of tiotropium combined with formoterol and salmeterol in the treatment of patients with chronic obstructive pulmonary disease

Effect of low dose of inhaled corticosteroid combined with asmeton on treatment of bronchial asthma

Efficacy of triple therapy inhalers in acute exacerbations of chronic obstructive pulmonary disease

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study

Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma-COPD overlap syndrome

[Combination of Inhaled Salmeterol/fluticasone and Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: a Randomised Controlled Trial].

Effect of corticosteroid inhalation and acupoint sticking on immune function in asthmatic children

Efficacy and Safety of Budesonide/formoterol Single Inhaler Therapy Versus Budesonide Inhaler Plus Formoterol Inhaler in Asthma Patients

Assessment of anti-inflammatory effect from addition of a long-acting beta-2 agonist to inhaled corticosteroid

The Efficacy of Budesonide-formoterol in Patients with Acute Attacks of Mild-to-moderate Bronchial Asthma: An Observational Study